TAKE Limited Reports Q1 FY27 Profit Amid Strategic Rebranding

Consolidated Net Profit: ₹1.06 crore (₹106.26 lakh)
Revenue from Operations: ₹30.37 crore (₹3,037.33 lakh)

Reader Takeaway: Profitability returns with a new strategy focused on high-growth health-tech sectors.

What just happened

TAKE Limited, formerly TAKE Solutions Limited, has reported a consolidated net profit of ₹1.06 crore for the first quarter of fiscal year 2027. This marks a substantial improvement from a net loss of ₹91 lakh in the same quarter last year. The company also officially changed its name and is strategically pivoting towards the longevity, biohacking, and preventive healthcare markets.

Why this matters

This development signifies a crucial turnaround for the company, moving from a loss-making position to profitability. The strategic shift into the growing preventive healthcare sector, integrating nutraceuticals with digital tools, could unlock new revenue streams and higher margins, potentially benefiting shareholders if executed successfully.

The backstory

The company operated as TAKE Solutions Limited, with its financial performance in the previous year's first quarter showing a net loss. The rebranding to TAKE Limited and the strategic focus on longevity and biohacking represent a significant departure from its previous business lines.

What changes now

TAKE Limited is now positioning itself as a player in the health-tech and wellness industry, focusing on science-backed nutraceuticals and digital health tools. This new direction aims for predictable, margin-accretive revenue from consumer wellness categories.

Risks to watch

The success of this new strategy hinges on effective execution in a competitive and specialized market. Building brand recognition and market share in longevity and biohacking will require significant investment and different capabilities than its legacy business.

Peer comparison

Companies in the biohacking and preventive healthcare space often focus on R&D and direct-to-consumer models. TAKE Limited's approach of integrating technology with nutraceuticals will need to find its niche against established players and emerging startups in this sector.

Context metrics (time-bound)

• Q1 FY27 Revenue: ₹30.37 crore (₹3,037.33 lakh) consolidated.
• Q1 FY27 Net Profit: ₹1.06 crore (₹106.26 lakh) consolidated.
• Q1 FY26 Net Loss: -₹91.00 lakh consolidated.
• Standalone Revenue Q1 FY27: ₹11.97 crore.
• Standalone Net Profit Q1 FY27: ₹0.97 crore.
• Consolidated Finance Costs Q1 FY27: ₹0.07 lakh.
• Basic and Diluted EPS Q1 FY27: ₹0.07.

What to track next

Investors will be closely watching the company's commercialization efforts in the longevity and biohacking market, its customer acquisition strategies, and the sustained profitability of its new business model.